[Ranibizumab and exudative age-related macular degeneration: 5-year multicentric functional and anatomical results in real-life practice]. / Ranibizumab et dégénérescence maculaire liée à l'âge exsudative : analyse multicentrique à 5ans des résultats fonctionnels et anatomiques en pratique clinique réelle.
J Fr Ophtalmol
; 39(8): 668-674, 2016 Oct.
Article
in Fr
| MEDLINE
| ID: mdl-27609025
ABSTRACT
PURPOSE:
The goal of this study was to evaluate five year functional and anatomical outcomes of wet AMD patients treated with ranibizumab according to a pro re nata (PRN) regimen in real-life practice.METHODS:
A retrospective, multicentric chart review of 201 eyes of 201 patients who underwent their first ranibizumab intravitreal injection (IVT) between January 1, 2007 and December 31, 2008 was performed. Best-corrected visual acuity (BCVA), central macular thickness (CMT) on SD-OCT, number of IVT and follow-up visits were collected at baseline and during the entire follow-up period of 5 years.RESULTS:
Mean BCVA at baseline was 52.3±16.5 letters. Mean BCVA change from baseline was respectively +2.8, +2.5, +1.8, -0.6 at 1, 2, 3, 4 years of follow-up. At year 5, 43% of eyes had a stable or improved letter score (≥0 letter gain), whereas 29% declined by 15 letters or more, with an overall significant mean decline of 2.8 letters (P<0.05). No correlation was observed between final visual outcome and age, baseline BCVA, type of neovascularization, naive status, number of IVT or number of follow-up visits. On SD-OCT, mean CMT was 293±96µm at baseline and was significantly reduced compared to baseline at each year end-point (P<0.005). The mean number of IVT was 15±10.4 at year 5, with 55% of eyes still being under active treatment.CONCLUSION:
PRN ranibizumab in real-life practice improved or stabilized visual acuity over 4 years. During the 5th year, progressive decline of visual acuity was observed.Key words
Full text:
1
Collection:
01-internacional
Database:
MEDLINE
Main subject:
Visual Acuity
/
Angiogenesis Inhibitors
/
Wet Macular Degeneration
/
Ranibizumab
Type of study:
Observational_studies
/
Prognostic_studies
Limits:
Aged
/
Aged80
/
Female
/
Humans
/
Male
Language:
Fr
Journal:
J Fr Ophtalmol
Year:
2016
Type:
Article
Affiliation country:
France